InvestSMART

Proteomics International Laboratories Ltd (ASX:PIQ)

ALERT: Price-sensitive ASX Announcement for PIQ
Current share price for PIQ : $0.155 -0.375 (-70.75%)+
Announcement
Release
17 Dec 2025 8:33AM
Price at Release
$0.530
Full Release
download
Summary
Proteomics International Laboratories Ltd (ASX: PIQ) announced securing a US patent for its PromarkerEso diagnostic test, a proprietary blood test designed for the early detection of esophageal adenocarcinoma (EAC). This patent, titled 'Glycoprotein Biomarkers For Esophageal Adenocarcinoma And Barrett's Esophagus And Uses Thereof', is a significant step in the company's commercialisation strategy, offering potential for partnerships, licensing, and regulatory progress in the US, the world's largest healthcare market. EAC is a serious health concern often related to chronic acid reflux, with a high rate of undetected cases until late stages. The PromarkerEso test combines biomarkers and clinical factors to provide a risk score, aiming to improve early detection and reduce healthcare costs. The patent also covers Australia, China, Hong Kong, and Europe, extending protection until 2036.
Key Points
  • US patent granted for PromarkerEso diagnostic test.
  • PromarkerEso addresses unmet needs in early EAC diagnosis.
  • EAC often goes undetected until late stages.
  • Patent protection covers multiple jurisdictions.
  • The granted patent supports commercialisation in the US market.
  • PromarkerEso offers a non-invasive alternative to endoscopy.
  • Patent extends protection until 2036.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.